Replies to post #30339 on Biotech Values

[Biowatch]

re: Erbitux usage: I thought IMCL gave a breakdown of Erbitux usage (or market penetration?) in 1st, 2nd, and 3rd line CRC treatment in one of their CCs, but I don't have the link.

I think you posted it after a CC...